SREBF2 and X-linked adrenoleukodystrophy: The PPARα agonist fenofibrate has also been shown to activate SREBF2 (Rampler et al., 2003) and to have therapeutic potential for the treatment of adrenoleukodystrophy (Berger et al., 2010), consistent with the possibility that this drug may stimulate myelination.